The observational study, presented by Harshal Deshmukh (University of Hull, UK) at the 82nd ADA Scientific Sessions in New Orleans, Louisiana, was based on data collected from a nationwide UK audit of people with diabetes (96% type 1 diabetes) using the FreeStyle Libre flash glucose monitor from November 2017 until August 2021.

They follow on from successful 3-month results that were reported  at the same conference in 2021.

They call for further studies to “unravel” the association between obesity and type 1 diabetes “so that we can better address the full spectrum of risks posed by the obesity epidemic or identify common environmental factors affecting both weight and type 1 diabetes.” medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group Diabetologia 2022; doi:10.1007/s00125-022-05722-5 ADA Scientific Sessions; New Orleans, Louisiana: 3–7 June 2022

The researchers also presented their findings at the virtual ADA 81st Scientific Sessions. medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group ADA Scientific Sessions; 25–29 June 2021 N Engl J Med 2021; doi:10.1056/NEJMoa2108269

The newly published ADA/EASD consensus report on the management of type 1 diabetes provides a comprehensive overview of the care required to help people with the condition live a full and healthy life.

Parth Narendran gives his highlights of the ADA/EASD type 1 diabetes management consensus report, and explains how it can support clinicians to deliver improved services for their patients.

Anne Peters talks about the goals of the ADA/EASD type 1 diabetes management consensus report, the issues to urgently address, and the joys of being part of a trans-Atlantic collaboration.

Robert Kushner (Northwestern University, Chicago, Illinois, USA) presented the cardiometabolic outcomes, Leigh Perreault (University of Colorado Anschutz Medical Campus, Aurora, USA) the metabolic findings, and Ildiko Lingvay (University of Texas Southwestern Medical Center, Dallas, USA) the impact of baseline variables. medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group ADA Scientific Sessions; 25–29 June 2021 (Abstract 80-OR) ADA Scientific Sessions; 25–29 June 2021 (Abstract 82-OR) ADA Scientific Sessions; 25–29 June 2021 (Abstract 83-OR)

Findings from two studies presented at the virtual ADA 81st Scientific Sessions suggest that cardiovascular autonomic neuropathy is associated with an increased risk for kidney function decline and heart failure in people with type 2 diabetes.

An international expert group organized by the ADA has published consensus definitions of type 2 diabetes remission.

For the obesity-specific IWQOL-Lite-CT questionnaire, the degree of improvement was similar for all activities. medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group ADA Scientific Sessions; 25–29 June 2021 (Abstract 84-OR) ADA Scientific Sessions; 25–29 June 2021 (Abstract 85-OR)

In this study, Prahalad and colleagues found that the 89 participants undergoing CGM with remote monitoring had lower average HbA1c levels than the 47 given CGM alone at the 6-month follow-up, at 6.69% versus 6.88% (50 vs 52 mmol/mol), and this difference was maintained at 12 months, at 7.32% versus 7.56% (57 vs 59 mmol/mol). medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group ADA Scientific Sessions; 25–29 June 2021 (abstract 69-OR) ADA Scientific Sessions; 25–29 June 2021 (abstract 916-P)

The researchers also presented their findings at the virtual ADA 81st Scientific Sessions. medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group ADA Scientific Sessions; 25–29 June 2021 Diabetes Care 2021; doi:10.2337/dc21-0028

Most gastrointestinal events occurred during the dose-escalation period; all participants started tirzepatide at 2.5 mg/week, escalating to the target dose over 4 to 20 weeks. medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group ADA Scientific Sessions; 25–29 June 2021 N Engl J Med 2021; doi:10.1056/NEJMoa2107519 N Engl J Med 2021; doi:10.1056/NEJMe2109957

But they say that the results of SURPASS-CVOT, due in 2024, “will be pivotal in reassuring clinicians that twincretins indeed represent the next step in type 2 diabetes treatment.” medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group ADA Scientific Sessions; 25–29 June 2021 Lancet 2021; doi:10.1016/S0140-6736(21)01324-6 Lancet 2021; doi:10.1016/S0140-6736(21)01390-8

Murphy cautioned that use of a 6.5 cm silastic ring in this study, to prevent gastric pouch dilation, means the results may not apply to unbanded RYGB. medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group ADA Scientific Sessions; 25–29 June 2021

However, Hallström stressed that macroalbuminuria and HbA1c had the strongest associations. medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group ADA Scientific Sessions; 25–29 June 2021

The safety profile of efpeglenatide was as expected for a medication from the glucagon-like peptide-1 receptor agonist class, with diarrhea, nausea, and vomiting the most frequent events. medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group ADA Scientific Sessions; 25–29 June 2021

He noted, however, that the trial did not include sodium-glucose cotransporter-2 inhibitors, which are commonly used in current clinical practice, and that the findings may not be generalizable to people with newly diagnosed or longstanding type 2 diabetes. medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group ADA Scientific Sessions; 25–29 June 2021 Patrick Holmes discusses whether the GRADE study answers the question of which type 2 diabetes medication should be used after metformin, and comments on the generalizability of the findings (3:54).

Arnold closed her presentation by emphasizing the need for “greater targeting of medications to patients with established cardiovascular disease as these are the highest-risk patients [who stand to gain] the greatest amount of benefit.” medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group ADA Scientific Sessions; 25–29 June 2021